Skip to content

the Effect of Smoking on the Effectiveness of Peribulbar Anesthesia in pars plant vitrectomy

the Effect of Smoking on the Effectiveness of Peribulbar Anesthesia in pars plant vitrectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111333
Enrollment
Unknown
Registered
2025-10-29
Start date
2024-06-17
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitreoretinal disease

Interventions

Active smoking group (nicotine hyperdependence):NO
Active smoking group (nicotine low dependence):NO
Passive smoking group:NO

Sponsors

The First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients who undergo pars plant vitrectomy for the first time and meet the following criteria: 1. Age 18-70 years; 2. Patients with diabetic retinopathy, central or branch retinal vein occlusion, retinal detachment, macular retinopathy, etc., requiring pars plant vitrectomy ; 3. Subject can communicate fluently with doctors.

Exclusion criteria

Exclusion criteria: 1. Subjects have keratitis, anterior chamber inflammation, uveitis, etc.; Patients with a history of orbital malformation and orbital surgery; Patients with ocular trauma need to be excluded due to the increase in orbital pressure after injection of anesthetic, temporary mild protrusion of the eyeball, and the use of peribulbar will increase the loss of ocular content; Corneal degeneration causes corneal thinning or other similar conditions, and peribulbar anesthesia is not suitable for those who are not suitable for corneal degeneration; 2. Subject has serious underlying diseases other than eye diseases, which in the opinion of the investigator may affect the treatment, evaluation or compliance of the patient with the study protocol, including: heart failure, respiratory failure, neurological or psychiatric diseases (including alcohol consumption or drug abuse), hematologic diseases (coagulation dysfunction), immune system diseases (such as AIDS), infectious diseases (such as syphilis), malignant tumors or organ transplantation, etc.; 3. Those who are known to be allergic to local anesthetics; 4. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Total anesthetic dose;

Secondary

MeasureTime frame
Onset time of sensory block;Onset time of motor block ;Grade of anesthetic effect;

Countries

China

Contacts

Public ContactXuhui Yu

The First Affiliated Hospital of Harbin Medical University

liyali5791@163.com+86 182 9151 5791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026